Growth hormone secretagogues
Compounds studied in the literature for their interaction with the growth hormone secretagogue receptor (GHSR) and somatotropic axis research.
11 compounds
CJC-1295 (no DAC)
A 29-residue analog of growth hormone-releasing hormone (GHRH) with modifications at positions 2, 8, 15, and 27 for enhanced in vitro stability.
CJC-1295 (with DAC)
The drug-affinity-complex (DAC) modified variant of CJC-1295 — a GHRH analog with a lysine linker and maleimido-propionic acid for extended serum half-life in research models.
Ipamorelin
A pentapeptide studied as a selective ghrelin-receptor (GHSR) agonist in growth hormone secretagogue research.
Sermorelin
The 29-residue active fragment of human GHRH (GRF 1-29). Studied as a reference GHRH-receptor agonist.
Tesamorelin
A stabilized GHRH analog with N-terminal trans-3-hexenoyl modification. Studied in GHRH-receptor research.
GHRP-2
A hexapeptide growth-hormone-releasing peptide studied in GHS-R1a receptor research.
GHRP-6
A hexapeptide GH secretagogue — reference compound in ghrelin-receptor research.
Hexarelin Acetate
A synthetic hexapeptide GH secretagogue — the 2-methyl-Trp variant of GHRP-6 with enhanced in vitro activity.
MGF (Mechano Growth Factor)
The splice variant of IGF-1 (IGF-1Ec) studied in muscle satellite cell and tissue research literature.
IGF-1 LR3
A long-R3 insulin-like growth factor 1 analog with reduced IGFBP affinity. Reference compound in IGF-1 receptor research.
HGH Fragment 176-191
A 16-residue C-terminal fragment of human growth hormone studied in adipocyte research literature.